EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

c-MET Overexpression Drives AKT Activation, and Combined Inhibition Synergistically Enhances Therapeutic Sensitivity in Non-Small-Cell Lung Cancer

Pratheesh Kumar Poyil iD, Rafia Begum, Saravanan Thangavel, Khadija Al-Obaisi, Abdul K Siraj

Cells · 25.06.2026 · 15 (13) · 1155

DOI: 10.3390/cells15131155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 25.06.2026. Verfasst von Pratheesh Kumar Poyil und 4 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Therapeutics, Research & Innovation, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins c-met, Proto-Oncogene Proteins c-akt, Lung Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant activation of c-MET signaling contributes to tumor progression and resistance to therapy in non-small-cell lung cancer (NSCLC), yet its therapeutic significance remains incompletely understood. In this study, we evaluated c-MET expression and its association with AKT activation and clinical outcomes using a tissue microarray cohort and publicly available datasets. c-MET overexpression was significantly associated with increased p-AKT expression and showed a trend toward poorer overall survival in the tissue microarray cohort, while analysis of the TCGA LUAD dataset confirmed a significant association with reduced survival (log-rank p = 0.0223; HR = 1.234, 95% CI: 1.029–1.480). Functional studies demonstrated that pharmacological inhibition of c-MET suppressed cell proliferation and induced caspase-dependent mitochondrial apoptosis in NSCLC cell lines. Mechanistically, c-MET inhibition resulted in AKT inactivation, identifying AKT as a key downstream mediator of c-MET signaling. Notably, combined inhibition of c-MET (PHA665752) and AKT (MK2206) exhibited strong synergistic effects, significantly enhancing apoptosis and reducing cell viability compared to single-agent treatments. These findings were further validated in vivo, where combination therapy markedly delayed tumor growth without significant toxicity. Collectively, our results highlight c-MET-driven AKT activation as a key oncogenic mechanism and support dual c-MET/AKT targeting as a promising therapeutic strategy for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProto-Oncogene Proteins c-metProto-Oncogene Proteins c-aktLung NeoplasmsHumansCell Line, TumorAnimalsApoptosisCell ProliferationFemaleMice, NudeSignal TransductionSulfonesMiceDrug SynergismGene Expression Regulation, NeoplasticIndolesHeterocyclic Compounds, 3-RingXenograft Model Antitumor AssaysProtein Kinase Inhibitors

Stichwörter der Autor:innen

AKT signalingapoptosisc-METcombination therapynon-small-cell lung cancer (NSCLC)

Substanzen

Proto-Oncogene Proteins c-metProto-Oncogene Proteins c-aktSulfonesIndolesHeterocyclic Compounds, 3-RingProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Experimental Therapeutics, Research & Innovation, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
  • Genomic Analytics, Research & Innovation, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
  • Translational Oncology Research, Research & Innovation, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.

ORCID-Profile: Pratheesh Kumar Poyil

Zitieren

APA

Poyil, P. K., Begum, R., Thangavel, S., Al-Obaisi, K., & Siraj, A. K. (2026). c-MET Overexpression Drives AKT Activation, and Combined Inhibition Synergistically Enhances Therapeutic Sensitivity in Non-Small-Cell Lung Cancer. Cells, 15(13), 1155. https://doi.org/10.3390/cells15131155

Vancouver

Poyil PK, Begum R, Thangavel S, Al-Obaisi K, Siraj AK. c-MET Overexpression Drives AKT Activation, and Combined Inhibition Synergistically Enhances Therapeutic Sensitivity in Non-Small-Cell Lung Cancer. Cells. 2026;15(13):1155. doi:10.3390/cells15131155

BibTeX
@article{Poyil2026,
  author = {Poyil, Pratheesh Kumar and Begum, Rafia and Thangavel, Saravanan and Al-Obaisi, Khadija and Siraj, Abdul K},
  title = {c-MET Overexpression Drives AKT Activation, and Combined Inhibition Synergistically Enhances Therapeutic Sensitivity in Non-Small-Cell Lung Cancer},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {1155},
  doi = {10.3390/cells15131155}
}
Kostenlos starten →